The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis

被引:0
作者
Qin, Zhaohui [1 ]
He, Meng [2 ]
Shen, Huangying [2 ]
Liu, Sha [3 ]
Xu, Shuo [2 ]
Chen, Lijiang [4 ]
机构
[1] Xuzhou Med Univ, Res Ctr Med & Hlth Emergency Rescue, Clin Med Sch 2, Xuzhou, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Sch Management, Xuzhou, Jiangsu, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Med & Hlth Management, Wuhan, Peoples R China
[4] First Hosp Nanping, Nanping, Peoples R China
关键词
drug cost; national drug price negotiation; health policy; interrupted time series analysis; patient burden; CANCER DRUGS; REGRESSION; INSURANCE;
D O I
10.3389/fpubh.2024.1381786
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background To reduce the burden of patients' medical care, the Xuzhou Municipal Government has initiated an exploratory study on the supply model and categorized management of nationally negotiated drugs. This study aims to understand the extent to which Xuzhou's 2021 reform of the National Drug Price Negotiation (NDPN) policy has had a positive impact on the healthcare costs of individuals with different types of health insurance. Methods The Interrupted Time Series Analysis method was adopted, and the changes in average medical expenses per patient, average medical insurance payment cost per patient and actual reimbursement ratio were investigated by using the data of single-drug payments in Xuzhou from October 2020 to October 2022. Results Following the implementation of the policy, there was a significant decrease in the average medical expenses per patient of national drug negotiation in Xuzhou, with a reduction of 62.42 yuan per month (p < 0.001). Additionally, the average medical insurance payment cost per patient decreased by 44.13 yuan per month (p = 0.01). Furthermore, the average medical expenses per patient of urban and rural medical insurance participants decreased by 63.45 yuan (p < 0.001), and the average monthly medical insurance payment cost per patient decreased by 57.56 yuan (p < 0.04). However, the mean total medical expenditures for individuals enrolled in employee medical insurance decreased by 63.41 yuan per month (p < 0.001), whereas the monthly decrease was 22.11 yuan per month (p = 0.21). On the other hand, there was no discernible change in the actual reimbursement ratio. Conclusion After the adoption of the NDPN policy, a noticeable decline has been observed in the average medical expenses per patient and the mean cost of the average medical insurance payment per patient, although to a limited extent. Notably, the reduction in employee medical insurance surpasses that of urban and rural medical insurance.
引用
收藏
页数:8
相关论文
共 26 条
  • [1] The Effects of Medicare on Medical Expenditure Risk and Financial Strain
    Barcellos, Silvia Helena
    Jacobson, Mireille
    [J]. AMERICAN ECONOMIC JOURNAL-ECONOMIC POLICY, 2015, 7 (04) : 41 - 70
  • [2] A methodological framework for model selection in interrupted time series studies
    Bernal, J. Lopez
    Soumerai, S.
    Gasparrini, A.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2018, 103 : 82 - 91
  • [3] Interrupted time series regression for the evaluation of public health interventions: a tutorial
    Bernal, James Lopez
    Cummins, Steven
    Gasparrini, Antonio
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2017, 46 (01) : 348 - 355
  • [4] CLIFF A, 1972, GEOGR ANAL, V4, P267
  • [5] Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience
    Dunlop, William C. N.
    Staufer, Alexandra
    Levy, Pierre
    Edwards, Guy J.
    [J]. HEALTH POLICY, 2018, 122 (05) : 528 - 532
  • [6] Reference pricing for pharmaceuticals: is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?
    Faunce, Thomas A.
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2007, 187 (04) : 240 - 242
  • [7] A global comparison of the cost of patented cancer drugs in relation to global differences in wealth
    Goldstein, Daniel A.
    Clark, Jonathon
    Tu, Yifan
    Zhang, Jie
    Fang, Fenqi
    Goldstein, Robert
    Stemmer, Salomon M.
    Rosenbaum, Eli
    [J]. ONCOTARGET, 2017, 8 (42) : 71548 - 71555
  • [8] Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study
    Hsu, Jason C.
    Lu, Christine Y.
    [J]. BMJ OPEN, 2016, 6 (06):
  • [9] Examining the density in out-of-pocket spending share in the estimation of catastrophic health expenditures
    Jbaily, Abdulrahman
    Haakenstad, Annie
    Kiros, Mizan
    Riumallo-Herl, Carlos
    Verguet, Stephane
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2022, 23 (05) : 903 - 912
  • [10] Does the separating of hospital revenue from drug sales reduce the burden on patients? Evidence from China
    Li, Lele
    Yu, Qiao
    [J]. INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH, 2021, 20 (01)